Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06205485 · ClinicalTrials.gov registry record · Phase 3
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
A Phase 3 study of Rectal Cancer, sponsored by Canadian Cancer Trials Group.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 250
- Enrollment target
- 20
- Study locations
NCT06205485: Recruiting Phase 3 study of Rectal Cancer, sponsored by Canadian Cancer Trials Group.
NCT06205485 is a Phase 3 study of Rectal Cancer that is actively recruiting participants, run by Canadian Cancer Trials Group. The registered enrollment target is 250 participants, below the 3,163-participant average among 70 other Rectal Cancer trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06205485, a Phase 3 study of Rectal Cancer, is actively recruiting participants, sponsored by Canadian Cancer Trials Group.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 250 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemotherapy alone is given before limited surgery compared to chemotherapy and radiation therapy given together before limited surgery? If radiation therapy is not given, is quality of life better?
Conditions Studied
Interventions
- DRUG Capecitabine
- DRUG Leucovorin
- DRUG Oxaliplatin
- RADIATION Radiation
- DRUG Fluoruracil
Study Locations (20)
Illinois
- Rush-Copley Medical Center - Aurora
- Northwestern University - Chicago
- Carle at The Riverfront - Danville
- Northwestern Medicine Cancer Center Kishwaukee - DeKalb
- Carle Physician Group-Effingham - Effingham
- Northwestern Medicine Cancer Center Delnor - Geneva
- Carle Physician Group-Mattoon/Charleston - Mattoon
- Carle Cancer Center - Urbana
California
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care - Irvine
- Los Angeles General Medical Center - Los Angeles
- USC / Norris Comprehensive Cancer Center - Los Angeles
- UC Irvine Health/Chao Family Comprehensive Cancer Center - Orange
Delaware
- Beebe South Coastal Health Campus - Millville
- Helen F Graham Cancer Center - Newark
- Medical Oncology Hematology Consultants PA - Newark
- Beebe Health Campus - Rehoboth Beach
Georgia
- Emory University Hospital Midtown - Atlanta
- Emory University Hospital/Winship Cancer Institute - Atlanta
- Emory Saint Joseph's Hospital - Atlanta
Arizona
- Cancer Center at Saint Joseph's - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2024-06-26 |
| Est. Completion | 2030-06-30 |
| Phase | Phase 3 |
What NCT06205485 shows while recruiting
NCT06205485 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 3,163-participant average among 70 other Rectal Cancer trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Rectal Cancer appearing as the primary indexed condition, and to 5 interventions - of which Capecitabine is the first listed.
NCT06205485 names 20 study sites across 5 states, led by Illinois, California, Delaware.
Frequently Asked Questions
What is clinical trial NCT06205485 about?
NCT06205485 is a clinical study titled "Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer". This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemotherapy alone is given before limited surgery compared to chemotherapy and radiation therapy given together before limited surgery? If radiation therapy is not given, is quality of ...
What is the current status of trial NCT06205485?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 250 participants. The study started on 2024-06-26. Estimated completion is 2030-06-30.
What conditions does trial NCT06205485 study?
This clinical trial studies the following conditions: Rectal Cancer.
What interventions are being tested in trial NCT06205485?
The interventions under investigation include: Capecitabine (DRUG), Leucovorin (DRUG), Oxaliplatin (DRUG), Radiation (RADIATION), Fluoruracil (DRUG).
Who is sponsoring clinical trial NCT06205485?
This trial is sponsored by Canadian Cancer Trials Group, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06205485 being conducted?
This trial has 20 study locations across Arizona, California, Delaware, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06205485's enrollment target sits among peer trials
250 14th of 70 higher than 56 of 70 other Rectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial
ACTIVE NOT RECRUITING · Phase 3
-
Promoting Physical Activity After Colorectal Cancer
COMPLETED · Phase 3
-
An Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy
COMPLETED · Phase 3
-
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
RECRUITING · Phase 1
-
Exosomes in Rectal Cancer
RECRUITING
-
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy